Citations

Clear

4207 citation(s) found for "Chen, S".

Glucagon-Like Peptide-1 Receptor Agonists for Patients with Conservatively Managed Nontraumatic Subdural Hematoma
Chen, Huanwen , McIntyre, Matthew K. , Kakadiya, Jay , Rai, Pranjal , Essibayi, Muhammed Amir , Salim, Hamza , Mandel, Daniel M, Buzzeli, Marc, Yedavalli, Vivek , Gandhi, Dheeraj, Azzam, Ahmed Y , Essibayi, Muhammed Amir , Salim, Hamza , Yedavalli, Vivek S , Dmytriw, Adam A , Malhotra, Ajay , Colasurdo, Marco , Lakhani, Dhairya , Kakadiya, Jay , Rai, Pranjal , Dmytriw, Adam A. , Malhotra, Ajay , Gandhi, Dheeraj , Colasurdo, Marco , Lakhani, Dhairya A. , Chen, Huanwen

Mayo Clinic

Neurosurgery | August 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1227/neu.0000000000004193 | PMID 42599090 Get It

BACKGROUND AND OBJECTIVES: Medical management options for nontraumatic subdural hematoma (SDH) remain limited, with only atorvastatin demonstrating benefit in a single phase 2 randomized clinical trial and mixed evidence for dexamethasone. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may benefit SDH outcomes. The objective of this study was to evaluate the association between GLP-1 RA use and rescue surgery rates and mortality in patients with medically managed nontraumatic SDH. METHODS: We conducted a retrospective cohort study using the TriNetX database from 2016 to 2025, including adults with SDH who were managed conservatively without surgical evacuation or middle meningeal artery embolization. Patients prescribed GLP-1 RAs were compared with nonusers. After propensity matching, rescue surgical evacuation, all-cause mortality at 1 year, and GLP-1 RA–associated adverse events were analyzed. RESULTS: A total of 134 901 patients with conservatively managed nontraumatic SDH were identified, of whom 1470 (1.1%) were GLP-1 RA users. After propensity score matching, 2922 patients remained, with 1461 in each group. At 1 year, GLP-1 RA users experienced significantly lower rates of rescue surgery (2.23% vs 3.51%; P = .046), culminating in an overall 38% reduction in relative hazard. All-cause mortality was also significantly lower for GLP-1 RA users at 1 year (16.1% vs 23.7%, P < .001), reflecting a 33% reduction in hazards. GLP-1 RA users did not experience different rates of adverse events, such as pancreatitis, gallbladder disease, or ileus/bowel obstruction (all P > .05). CONCLUSION: Among patients with medically managed nontraumatic SDH, GLP-1 RA use was associated with significantly lower rates of rescue surgery and all-cause mortality without significantly increased risk of common GLP-1 RA–related complications.
Review Article: Immune Effector Cell‐Mediated Enterocolitis Following CAR ‐T Cell Therapy—Clinical Features, Pathophysiology and Management
Lin, Yi , Chen, Zongming Eric, Lim, Kenneth J C , Chowla, Navreet , Damianos, John A , Lin, Yi , Lim, Kenneth J C , Chowla, Navreet M, Damianos, John

Mayo Clinic

Alimentary Pharmacology & Therapeutics | August 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/apt.70920 | PMID 42596026 Get It

ABSTRACT Background Chimeric antigen receptor T‐cell (CAR‐T) therapy has revolutionised the treatment of hematologic malignancies, and its use is expanding rapidly into numerous other disease states including autoimmune diseases. However, CAR‐T therapy is associated with a spectrum of immune‐related toxicities. In addition to the already well characterized cytokine release syndrome and immune effector cell‐associated neurotoxicity syndrome, it has become apparent that rarely, CAR‐T can cause gastrointestinal mucosal inflammation, termed immune effector cell‐mediated enterocolitis (IEC‐EC). Aims This state‐of‐the‐art review highlights the CAR‐T mechanism and details the epidemiology, pathophysiology, clinical manifestations, endoscopic and histopathologic features, and management of IEC‐EC. Methods This review presents the current state of knowledge through a comperhensive and detailed synthesis of all case series reported in the literature to date. Results Occurring in up to approximately 6% of patients typically following B cell maturation antigen‐targeted CAR‐T therapy, IEC‐EC presents with severe diarrhoea and malabsorption, responds poorly to treatment, and portends a dire prognosis. Multi‐disciplinary management should centre on early diagnosis, supportive cares, assessment and treatment of infections, and step‐up pharmacotherapy, often featuring biologics and small molecules drawn from the inflammatory bowel disease pharmacologic armamentarium. Conclusions Clinicians should maintain a high degree of vigilance for IEC‐EC in patients presenting with gastrointestinal symptoms following CAR‐T treatment. Early recognition and multi‐disciplinary treatment may improve patient outcomes.
Multimodal Slice Interaction Network Enhanced by Transfer Learning for Precise Segmentation of Internal Gross Tumor Volume in Lung Cancer PET/CT Imaging
Luo, Yi , Guo, Yike, Zhang, Rui , Ngwa, Wil, Zhou, Zongwei, Ding, Kai , Hooshangnejad, Hamed , Feng, Xue, Chen, Quan , Ngwa, Wilfred , Zhou, Zongwei , Ding, Kai

Mayo Clinic

2026 IEEE 14th International Conference on Healthcare Informatics (ICHI) | August 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: 525-534

10.1109/ichi69079.2026.00072 Get It

Mechanistic Validation and Structural Analysis of PAH-Associated SOX17 for Real-World Relevance
Chen, Lingtao, Deng, Yuling, Tao, Cui, Nasif, Kazi Fahim Ahmad , Deng, Bobin, Xie, Yixin, Chen, Lingtao , Dai, Zhiyu , Niu, Shuteng , Tao, Cui , Deng, Bobin , Xie, Yixin

Mayo Clinic

2026 IEEE 14th International Conference on Healthcare Informatics (ICHI) | August 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: 574-581

10.1109/ichi69079.2026.00077 Get It

Genomically Adjusted Radiation Dose Predicts Outcomes in Pediatric Brain Tumors and Supports Biologically Personalized Radiotherapy
Joshi, Nikhil , Bergman, Drew T. , Nellore, Shivani, Chen, Peng, Murphy, Erin, Sheikh, Saad , LaRiviere, Michael J. , Foster, Jessica, Durkin, Jill, Matulis, Thomas, Nanda, Ronica, Yamoah, Kosj, Stapleton, Stacie, Beltran, Chris, Torres-Roca, Javier F., Scott, Jacob G., Foster, Jessica , Durkin, Jill, Ajao, Anuoluwapo , Nanda, Ronica H. , Yamoah, Kosj , Stapleton, Stacie L. , Eschrich, Steven A , Scott, Jacob Gardinier

Mayo Clinic

No container title available | August 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.08.09.26359976 Get It

ABSTRACT Background Radiotherapy is a cornerstone of treatment for pediatric central nervous system (CNS) tumors, but dose selection remains uniform despite interpatient variability in tumor radiosensitivity. This is consequential in children, for whom toxicity can have lifelong effects. Genomic-adjusted radiation dose (GARD) integrates tumor genomics with delivered radiation dose to quantify the biological effect of radiotherapy and has been validated across adult malignancies. Its relevance in pediatric CNS tumors is unknown. Methods We performed a cohort study using gene expression and data from 246 pediatric patients with high-grade glioma, medulloblastoma, or ependymoma from the Children’s Brain Tumor Network. GARD was calculated using a sequencing-adapted radiosensitivity index integrated with radiation dose through the linear–quadratic model. Associations of GARD and physical radiation dose with event-free and overall survival were evaluated using Cox proportional hazards models stratified by tumor type and anatomic location. Patients who did not receive radiotherapy comprised a negative control cohort (sham-GARD). Results Among patients receiving radiotherapy, physical dose was uniform, whereas GARD showed substantial interpatient variability in biological effect. Higher GARD was associated with improved event-free survival (hazard ratio [HR] 0·90, 95% CI 0·83–0·97; p=0·004) and overall survival (HR 0·90, 95% CI 0·83–0·99; p=0·018). Physical dose was not associated with either endpoint. Among patients who did not receive radiotherapy, sham-GARD was not associated with outcomes, supporting GARD as a treatment-specific predictor rather than a prognostic biomarker. Conclusions In pediatric CNS tumors, the biological effect of radiotherapy quantified by GARD was associated with outcomes, whereas physical dose was not. These findings challenge uniform radiotherapy dosing and support genomically informed dose individualization. Prospective evaluation of GARD-guided radiotherapy is warranted to optimize tumor control while minimizing long-term toxicity in children.
Elevated Endogenous Insulin and Insulin Resistance Are Associated With Progressive Diastolic Dysfunction and Worse Cardiovascular Outcomes
Adel, Fadi , Gochanour, Benjamin , Scott, Christopher G. , Singh, Jasraj , Malsawmzuali, JC, Ma, Xiaoyu , Chen, Horng H. , Adel, Fadi W , Scott, Christopher , Gochanour, Benjamin R.

Mayo Clinic

Circulation: Heart Failure | August 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1161/circheartfailure.126.014410 | PMID 42572892 Get It

BACKGROUND: Although diabetes is a known driver of heart failure with preserved ejection fraction, whether antecedent hyperinsulinemia drives preclinical diastolic dysfunction (DD) progression before overt hyperglycemia remains unknown. Therefore, we investigated whether elevated endogenous insulin and insulin resistance independently predict longitudinal DD progression and adverse cardiovascular outcomes. METHODS: In a community-based cohort study, we evaluated 1191 participants from the Olmsted County Heart Function Study (median age, 58.7 [interquartile range, 52.4–66.6 years]) who underwent echocardiography at baseline and after 4 years. Fasting insulin and homeostatic model assessment of insulin resistance were assessed. The primary end point was DD progression. Secondary outcomes (mortality, heart failure) were assessed in 2030 participants followed for a median of 10.97 (95% CI, 10.90–11.05) years for heart failure and a median of 18.1 (95% CI, 18.0–18.2) years for mortality. RESULTS: DD progression occurred in 7.5% of participants. Baseline fasting insulin and homeostatic model assessment of insulin resistance strongly predicted progression ( P <0.001). In multivariable analysis, every 1-SD increase in log-transformed insulin was associated with 65% increased odds of progression (odds ratio, 1.65 [95% CI, 1.33–2.07]; P <0.001), adjusting for age, creatinine, and NT-proBNP (N-terminal pro-B-type natriuretic peptide). Similar results were observed for homeostatic model assessment of insulin resistance (odds ratio, 1.66 [95% CI, 1.34–2.08]; P <0.001). In secondary analyses, elevated insulin independently predicted all-cause (hazard ratio, 1.11 per 1-SD [95% CI, 1.02–1.21]) and cardiovascular mortality (hazard ratio, 1.16 [95% CI, 1.02–1.33]). Homeostatic model assessment of insulin resistance was similarly predictive of all-cause (hazard ratio, 1.11 [95% CI, 1.03–1.20]) and cardiovascular mortality (hazard ratio, 1.16 [95% CI, 1.02–1.32]). CONCLUSIONS: Elevated endogenous insulin and insulin resistance are predictors of progressive DD and long-term mortality, even after accounting for body mass index. Metabolic dysregulation may drive myocardial stiffening before diabetes onset, identifying a potential early therapeutic window for heart failure with preserved ejection fraction prevention.
Bridging Restoration and Diagnosis: A Comprehensive Benchmark for Retinal Fundus Enhancement
Dong, Xuanzhao, Zhu, Wenhui, Chen, Xiwen, Wang, Hao, Li, Xin, Xiong, Yujian, Cheng, Jiajun , Wang, Zhipeng, Tang, Shao, Dumitrascu, Oana M., Wang, Yalin

Mayo Clinic

2026 IEEE/CVF Winter Conference on Applications of Computer Vision Workshops (WACVW) | August 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: 293-302

10.1109/wacvw68408.2026.00035 Get It

VAOT: Vessel-Aware Optimal Transport for Retinal Fundus Enhancement
Dong, Xuanzhao, Zhu, Wenhui, Xiong, Yujian, Chen, Xiwen, Wang, Hao, Li, Xin, Cheng, Jiajun , Wang, Zhipeng, Tang, Shao, Dumitrascu, Oana M., Wang, Yalin

Mayo Clinic

2026 IEEE/CVF Winter Conference on Applications of Computer Vision Workshops (WACVW) | August 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: 314-323

10.1109/wacvw68408.2026.00037 Get It

CoCoRV-nf: a powerful and cost-effective tool for rare variant analysis leveraging external biobank sequence data identified new candidate predisposition genes in amyotrophic lateral sclerosis and neuroblastoma
Tithi, Saima Sultana , Cooper-Knock, Johnathan, Benatar, Michael , Wuu, Joanne, Taylor, J Paul, Wu, Gang , Chen, Wenan , Cooper‐Knock, Johnathan , Wu, Gang , Wuu, Joanne , Taylor, J Paul

Mayo Clinic

Human Molecular Genetics | August 4, 2026 | Volume: 35 | Issue: 17 | Pages: No page available

10.1093/hmg/ddag076 | PMID 42574250 Get It

Abstract Although sequencing costs have steadily decreased with advances in technology, they remain high for large scale studies. The design of traditional individual-disease sequencing studies is either case only or cases with relatively few controls, resulting in potential loss of statistical power for discovery of disease associated genes. Here we show that for a given number of sequenced cases, a large control sample size is critical to maximize power for rare variant burden analysis. Furthermore, we have developed an end-to-end workflow based tool (CoCoRV-nf) to facilitate the use of external biobank sequence resources as controls. The modules include consistent variant QC, variant annotation, ancestry population prediction, and gene based burden analysis using summary genotype information, and combined analysis from multiple independent results. The tool supports exomes and genomes from gnomAD and All of Us as controls with preprocessed datasets. We apply the tool in two rare neurological diseases: amyotrophic lateral sclerosis and neuroblastoma. For each disease, two case cohorts are paired with gnomAD and All of Us data, respectively, followed by a combined analysis. Not only did we recapture known genes, but also, we identified new candidate genes for both diseases. By leveraging multiple large external biobank sequence data, we demonstrate the feasibility of using our tool to maximize statistical power to identify new disease predisposition genes.
CIP2A–TOPBP1 complex and PP2A dynamically regulate Polθ recruitment and phosphorylation at mitotic DNA double-strand breaks
Zhao, Xipeng , Chen, Bin , Xu, Feng, Zhang, Jie , Yao, Zhicheng, Wang, Ruru, Zhou, Shenglan, Hou, Yao, Xu, Shangkun, Xu, An, Wu, Lijun, Zhao, Guoping , Zhang, Jie , Zhang, Jie , Zhao, Guoping , Xu, An, Wu, Lijun

Mayo Clinic

Proceedings of the National Academy of Sciences | August 3, 2026 | Volume: 123 | Issue: 32 | Pages: No page available

10.1073/pnas.2600248123 | PMID 42546199 Get It

DNA double-strand breaks (DSBs) that occur during mitosis are primarily repaired by Polθ-mediated microhomology-mediated end joining (MMEJ). The CIP2A–TOPBP1 complex has been shown to tether broken chromatin at mitotic DSBs, but whether it coordinates with or functions independently of Polθ remains unknown. Here, we show that the CIP2A–TOPBP1 complex is recruited to mitotic DSB sites, where it directly interacts with Polθ and corecruits Polθ to chromatin. CIP2A sustains Polθ phosphorylation by inhibiting PP2A, thereby prolonging Polθ chromatin retention and enabling efficient repair. Upon repair completion, the CIP2A–TOPBP1 complex dissociates, PP2A dephosphorylates Polθ, and Polθ is released from chromatin. Loss of CIP2A impairs tumor growth, while disruption of CIP2A–Polθ binding leads to persistent DNA damage, micronucleus formation, and synthetic lethality in BRCA1/2-deficient cells. These findings uncover a cooperative mechanism by which CIP2A–TOPBP1 dynamically regulates Polθ in mitotic DSB repair and provide insights into the synthetic lethal interaction of CIP2A with BRCA1/2 under radiotherapy.